The clinical influence of preformed nonspecific anti‐HLA antibodies on single‐unit umbilical cord blood transplantation in patients with haematological malignancies.

The clinical influence of preformed nonspecific anti-HLA antibodies on single-unit umbilical cord blood transplantation in patients with haematological malignancies For over 30 years, umbilical cord blood transplantation (UCBT) has been an option available to patients who require allogeneic haematopoietic stem cell transplantation (allo-HSCT) but for whom a human leukocyte antigen (HLA)-matched sibling or unrelated donor is unavailable.1 Anti-HLA antibodies (AHAs) are antibodies that target class I and II HLA antigens and are mostly produced in response to foreign antigens during pregnancy, blood transfusion, or solid organ transplantation. Among the 392 patients, seventy-three patients (18.6%) were positive for AHAs and were considered the AHA-positive group, and the remaining 319 patients were considered the AHA-negative group. [Extracted from the article]